Thank you to the attendees for all their feedback. I noted from...

Thank you to the attendees for all their feedback.

I noted from the AGM presentation (page 13) Diagnostics and Life science
the TEM image of the Quantum Dots (Ellume ) & Mix & Go (Anteo) and reference to the partnership with Ellume  "partnering opportunities  .... Commercial value beginning "

Was any further info provided which expanded on the above or the ASX Announcement "Anteo Enters 5-year Agreementof ..." of 28th Oct 2016?

I assume the TEM image & the agreement relate specifically to the planned Ellume Flu test to be launched sometime in 2017?  (from Ellume web site).
I understood Ellume are awaiting some approvals ?? but had stated their capacity to produce some 2 mill tests ??

Can I ask if any more info was provided at the AGM, such as ....

- Process & expected timing for approvals of Ellume test & launch to market (US??),
- Anteo's current capacity to produce the agreed " long-term supply arrangement with minimum
annual requirements" and any contingency plans to increase capacity if market demand dictates,
- If the Ellume flu A/B test is our lead market product for launch in 2017 what are the full advantages offered to the patient/doctor/community and what is the competition and challenges for realizing Commercial value ??

Can anyone provide further information/thoughts please?

I must admit that I find the "Ellume solution" most appealing and very promising for our (Anteo's) future.

GLTH